Zimmer Partners’s BridgeBio Pharma BBIO Stock Holding History

Zimmer Partners’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-184,400	Closed	-$9.58M	–	128
2025 Q3	$9.58M	Buy	184,400 +4,300	+2%	+$210K	0.21%	79
2025 Q2	$7.78M	Sell	180,100 -121,300	-40%	-$4.41M	0.17%	91
2025 Q1	$10.4M	Buy	301,400 +121,000	+67%	+$4.08M	0.2%	83
2024 Q4	$4.95M	Buy	+180,400	New	+$4.66M	0.09%	104
2024 Q2	–	Sell	-73,200	Closed	-$2.26M	–	158
2024 Q1	$2.26M	Buy	73,200 +8,200	+13%	+$279K	0.05%	110
2023 Q4	$2.62M	Sell	65,000 -10,000	-13%	-$300K	0.1%	79
2023 Q3	$1.98M	Buy	+75,000	New	+$2.13M	0.05%	100
2020 Q1	–	Sell	-17,000	Closed	-$596K	–	80
2019 Q4	$596K	Hold	17,000	–	–	0.01%	78
2019 Q3	$365K	Hold	17,000	–	–	﹤0.01%	102
2019 Q2	$458K	Buy	+17,000	New	+$463K	﹤0.01%	100

Other funds holding BBIO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Zimmer Partners's BBIO Position: Q4 2025 in Review

Zimmer Partners sold out of BridgeBio Pharma (BBIO) in Q4 2025, closing a stake of 184,400 shares — an estimated $9.58M sold.

Zimmer Partners first reported a position in BBIO in Q2 2019 and held it in 10 quarters. The position peaked at $10.4M in Q1 2025. 433 funds tracked by Wall St. Rank hold BBIO as of Q4 2025.

Zimmer Partners reported no remaining BridgeBio Pharma position as of Q4 2025 after selling out during the quarter.
Zimmer Partners sold 184,400 BridgeBio Pharma shares in Q4 2025, an estimated $9.58M.
Zimmer Partners first reported a position in BridgeBio Pharma in Q2 2019 and held it in 10 quarters.
Zimmer Partners's BridgeBio Pharma position peaked at $10.4M in Q1 2025.
433 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q4 2025.

Based on Zimmer Partners's 13F filing for Q4 2025, filed 17 Feb 2026.